Featured Research

from universities, journals, and other organizations

Keloid development: New genes identified may unlock its mystery

Date:
May 29, 2014
Source:
Henry Ford Health System
Summary:
Previously unidentified genes that may be responsible for keloid scarring have been uncovered by researchers, a discovery that could unlock the mystery of keloid development and provide insight for more effective treatment. Keloid scars form raised, firm skin areas that may become itchy, tender, and painful. Unlike regular scars, keloids do not subside over time and often extend outside the wound site. Keloids most often occur on the chest, shoulders, earlobes (following ear piercing), upper arms and cheeks.

This image depicts Lamont R. Jones, M.D., vice chair, Department of Otolaryngology-Head and Neck Surgery at Henry Ford.

Researchers at Henry Ford Hospital in Detroit have uncovered previously unidentified genes that may be responsible for keloid scarring, a discovery that could unlock the mystery of keloid development and provide insight for more effective treatment.

"Much of the uncertainty surrounding keloids is rooted in there being no known cause for their development," says study lead author Lamont R. Jones, M.D., vice chair, Department of Otolaryngology-Head and Neck Surgery at Henry Ford.

"But it is believed that keloids have a genetic component given the correlation with family history, prevalence in twins, and its predisposition in darker skin."

Results from the study were presented this week at the American Academy of Facial Plastic and Reconstructive Surgery's 11th International Symposium in New York City.

Keloid scars form raised, firm skin areas that may become itchy, tender, and painful. Unlike regular scars, keloids do not subside over time and often extend outside the wound site.

Keloids most often occur on the chest, shoulders, earlobes (following ear piercing), upper arms and cheeks. The lowest rates of keloid formation have been documented in albinos and the highest seen in dark skinned individuals, especially in the African-American population.

Treatment for keloids includes cortisone injections, pressure dressings, silicone gels, surgery, cryosurgery (freezing), laser treatment, or radiation therapy. A combination of treatments may be used, depending on the individual.

In some cases, keloids return after treatment, up to 50 to 100 percent of the time.

For the Henry Ford study, Dr. Jones and his colleagues used six fresh keloid samples and six fresh normal skin samples in which genome-wide profiling was previously done. This effort identified 190 statistically significant regions of DNA that were mapped to 152 keloid specific genes.

The 152 genes were uploaded into the Ingenuity Pathway Analysis software, which integrates genes and molecules that are part of the same biological functions or regulatory networks interacting together.

Among 152 unique genes, the researchers found 10 genes that demonstrated an increase of the cellular components and regulatory pathways important to the biological processes in keloid development.

In all, the researchers were able to show that certain keloid genomes are present in known bionetwork pathways involved in critical biological functioning and signaling events in the cell.

Dr. Jones notes the importance of this new information and how it can be used to "further refine the screening process for biological significance in hopes of better understanding the pathogenesis and molecular targeted therapy for keloid disease."

"By identifying the genetic cause, it may be possible to develop better treatments for keloids in the near future," he says.


Story Source:

The above story is based on materials provided by Henry Ford Health System. Note: Materials may be edited for content and length.


Cite This Page:

Henry Ford Health System. "Keloid development: New genes identified may unlock its mystery." ScienceDaily. ScienceDaily, 29 May 2014. <www.sciencedaily.com/releases/2014/05/140529142400.htm>.
Henry Ford Health System. (2014, May 29). Keloid development: New genes identified may unlock its mystery. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/05/140529142400.htm
Henry Ford Health System. "Keloid development: New genes identified may unlock its mystery." ScienceDaily. www.sciencedaily.com/releases/2014/05/140529142400.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins